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Background: This study sought to evaluate the relation between long-term segmental and global functional outcome
after revascularisation in patients with chronic ischaemic left ventricular dysfunction (LVD) and baseline markers
of viability: late gadolinium enhancement (LGE) transmurality and contractile reserve (CR).
Methods: Forty-two patients with chronic ischaemic LVD underwent low-dose dobutamine- (LDD) and late gadolinium
enhancement (LGE) cardiovascular magnetic resonance (CMR) before surgical or percutaneous revascularisation. Regional
and global left ventricular (LV) functions and LGE were repeatedly assessed 6 ± 1 and 35 ± 6 months after revascularisation.
In total, 319 at baseline dysfunctional and successfully revascularised segments were available for statistical analysis.
Results: The likelihood of long-term functional improvement was directly related to the presence of CR and inversely
related to both the LGE and the degree of contractile dysfunction at baseline. The time course of functional
improvement was protracted, with significantly more delay in segments with more extensive LGE (p = 0.005) and
more severe contractile dysfunction at baseline (p = 0.002). The presence of CR was the predictor of earlier functional
improvement (p < 0.0001). Using a definition of viable segment as a segment without any LGE or with any LGE and
producing CR during LDD stimulation, ≥55% of viable segments from all dysfunctional and revascularised segments in
a patient was the only independent predictor of significant improvement (≥5%) in the left ventricular ejection fraction
(LVEF) after revascularisation, with a 72% sensitivity and an 80% specificity (AUC 0.76, p = 0.014). Reverse LV remodelling
was observed in patients who had a significant amount of viable myocardium successfully revascularised.
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Conclusions: In patients with chronic ischaemic LVD, improvement of dysfunctional but viable myocardium can be
considerably delayed. Both the likelihood and the time course of functional improvement are related to the LGE, CR
and the degree of contractile dysfunction at baseline. At 35 ± 6 months after revascularisation, patients with ≥55% of
viable segments from all dysfunctional and revascularised segments significantly improve LVEF and experience reverse
LV remodelling. A combination of LDD–CMR and LGE–CMR is a simple and powerful tool for identifying which patients
with impaired LV function will benefit from revascularisation.
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Functional improvement, Follow-up studiesBackground
Hibernating myocardium is normally defined as viable
and dysfunctional myocardium that improves in function
with restoration of adequate blood flow following revas-
cularisation [1]. This reversible state should be clearly
distinguished from irreversibly injured or infarcted myo-
cardium, in which case the restoration of coronary blood
flow would not be justified. The current role of viability
testing remains the prediction of potential functional
and clinical improvement in patients with impaired
LVEF, thereby facilitating a better estimate of the poten-
tial benefit of revascularisation therapy versus its risks
[2]. However, three prospective randomized trials—the
Heart Failure Revascularisation (HEART) Trial, the Posi-
tron emission tomography (PET) And Recovery following
Revascularisation (PARR-2) trial, and the Surgical Treat-
ment for Ischaemic Heart Failure (STICH) trial—have
challenged this concept, as none found benefit for the use
of viability testing in guiding management decisions or in-
fluencing mortality outcome [3-6]. The HEART trial ter-
minated prematurely and was not sufficiently powered to
draw conclusions [3]. The PARR-2 trial did not demon-
strate a benefit from PET-guided management compared
with standard care, although analysis of only those pa-
tients that did adhere to the PET-guided recommenda-
tions did reveal a significant mortality benefit [4]. The
STICH trial viability sub-study found that viability testing
did not alter outcomes (irrespective of management
strategy) [6]. However the latter sub-study had several
important methodological limitations [6]. Even after the
STICH trial, there is still a need for prospective studies
designed to clarify whether revascularisation of a sig-
nificant amount of hibernating myocardium is beneficial
compared with optimal medical therapy.
Cardiovascular magnetic resonance (CMR) with its high
spatial resolution, provides qualitative and quantitative,
global and regional information on myocardial anatomy
and function. In combination with a gadolinium-based
contrast agent, CMR allows an accurate quantification of
the myocardial scar [7] and predicts the likelihood of func-
tional recovery after revascularisation [8-11]. The cut-off
value of LGE used directly influences the technique’saccuracy for predicting functional recovery. As the cut-off
value for LGE increases, the sensitivity falls but specificity
rises. For example, >75% LGE has a 100% negative pre-
dictive value (NPV) for functional recovery after revascu-
larisation [8]. However, in patients with <75% LGE, the
additional assessment of CR by LDD-CMR improves the
predictive accuracy over LGE imaging alone [11-13].
Based on these insights, there is a rationale to combine
CMR-based viability parameters in order to better predict
improvement in dysfunctional myocardial segments after
revascularisation [11,14,15].
In most studies functional outcome is assessed 3–6
months after revascularisation, whereas a longer follow-up
interval would be more appropriate, taking into account
that functional recovery may be considerably delayed in
hibernating myocardium having more advanced structural
damage [10]. So far, few studies have investigated the
long-term functional outcome and time course of func-
tional recovery in relation to baseline markers of viability
[10,16-19]. To the best of our knowledge, the above-
mentioned studies didn’t explore CR and LGE, both
assessed by CMR as predictors of long-term segmental
and global left ventricular functional recovery.
To address the above-mentioned issues, we used CMR
to study a group of patients with chronic ischemic LVD
before and 6 ± 1 and 35 ± 6 months after revascularisation.
The primary goal of our study was to assess the long-term
functional outcome of left ventricular segmental and glo-
bal function after revascularisation in relation to baseline
markers of viability – CR and LGE. The second goal of
our study was to determine the optimal predictor of sig-
nificant (≥5%) improvement in LVEF at the end of study
period.
Methods
The methods have been described in detail before [12].
Patients and study design
A prospective evaluation of CMR based markers of viability
was performed in 42 patients with LVD (LVEF 36 ± 8%) be-
fore they underwent either surgical (n = 32) or percutan-
eous (n = 10) revascularisation. Three CMR scans were
Table 1 Baseline characteristics of the study patients
Patient characteristics
Males/females, n 39/3















Ejection fraction at baseline assessed by CMR, % 36 ± 8
Days between baseline CMR and revascularisation (range) 12 (2 – 33)
Treatment, %
Beta blockers 86
Angiotensin-converting enzyme inhibitors 71
Nitrates 69
NYHA functional class≥ III, % 79
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12 (range 2 – 33) days before revascularisation, a second
CMR scan 27 ± 4 weeks (6 ± 1 months) after revascularisa-
tion and a third CMR scan 151 ± 27 weeks (35 ± 6 months;
median 2.9 years, range 1.5 – 4.0 years) after revascularisa-
tion. The aim of CABG or PCI was to obtain complete
revascularisation, which was technically possible and per-
formed in all study patients. The short-term (6 months
after revascularisation) data on forty six consecutive pa-
tients meeting the following inclusion criteria: (1) coronary
artery disease (>70% stenosis in one or more major epicar-
dial vessels), scheduled for a revascularisation procedure;
(2) LVEF ≤45%; (3) at least two adjacent segments with wall
motion abnormalities at rest; (4) no infarction or revascu-
larisation within the last two months; and (5) no contrain-
dications to CMR (e.g., a pacemaker), has been published
previously [12]. Of the 4 patients who did not complete the
whole study, 2 had pacemakers or defibrillators implanted
during the period between follow-up CMR scans, 1 decided
not to undergo the third CMR scan because of a severe
disabling condition related to cerebral infarction, and 1
experienced sudden cardiac death in the period between
follow-up CMR scans. None of the patients were excluded
from the study for technical reasons or image quality. The
baseline characteristics of the 42 patients who underwent
all three CMR scans are listed in Table 1. All patients were
in stable clinical condition at the time of the CMR scans
and there was no clinical evidence of ischemic events dur-
ing the period between the revascularisation and the third
CMR scan. After revascularisation, all patients received
standard pharmacological treatment for heart failure, as
per current recommendations [20].
The study was approved by the Lithuanian Bioethics
Committee (No. 158200-13-576-178) and informed written
consent was obtained from each patient prior to inclusion
in the study.
CMR protocol
All the CMR scans were performed using a 1.5 Tesla MR
scanner (Avanto, Siemens Medical Solutions, Erlangen,
Germany) with the patient in a supine position, using pro-
spective electrocardiographic (ECG) gating. Steady-state
free precession cine CMR was performed while the breath
was held, and 4-, 3- and 2-chamber views, as well as a
short axis stack covering the left ventricle every 8 mm
without a gap, were acquired at rest and then after each
dose of dobutamine (5 and 10 μg/kg/min) (TE/TR/flip
angle 1.22 ms/63 ms/65 degrees, field of view (FOV)
250 mm, voxel size 1.9 × 1.3 × 8 mm3, matrix size 109 × 192).
After revascularisation, only rest images were acquired
using the same technique.
Ten to fifteen minutes after infusing 0.15 mmol/kg of
a commercially available gadolinium-based contrast agent
(gadopentetate dimeglumine or gadodiamide), an inversionrecovery gradient-echo sequence triggered to end-diastole
(TE/TR/flip angle 3.2 ms/700 ms/25 degrees, FOV
400 mm, matrix size 156 × 256 mm, and a typical voxel
size of 2.1 × 1.6 × 8 mm3) was performed with an inver-
sion time (240 to 330 ms) chosen to reduce the signal
from normal myocardium. Angulation was kept con-
stant for the short-axis and LGE imaging to enable a
match between the LGE and wall motion images. LGE
imaging was performed before revascularisation and
was repeated 6 ± 1 and 35 ± 6 months after revasculari-
sation in order to exclude from the study patients having
significant periprocedural injury (new LGE zones on second
CMR scan) or significant myocardial injury at follow-up
(new LGE zones on third CMR scan).
Post-processing analysis
We analysed the cine images and contrast-enhanced im-
ages using a model in which the LV was divided into 17
segments [21]. The wall motion was graded as 1 (normal),
2 (mild hypokinesia), 3 (severe hypokinesia), 4 (akinesia)
or 5 (dyskinesia) by 2 blinded investigators. For the pa-
tients undergoing percutaneous revascularisation, seg-
ments were considered to be undergoing revascularisation
according to the scheme suggested by Haug [22]. The LV
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territory according to the vessel anatomy on a conven-
tional angiogram. For the global LV functional analysis, all
short-axis slices from the base to the apex were analysed
with Argus software (Siemens) by two independent expe-
rienced observers (with certification of Level 2 compe-
tency in CMR and more than 5 years of work experience
in a CMR unit). Manual tracing of the left ventricular
endocardial borders of successive short-axis slices at end-
diastole and end-systole was performed (papillary muscles
were excluded from the volume calculations) in order to
calculate end-diastolic volume (EDV), end-systolic volume
(ESV), stroke volume (SV) and left ventricular ejection
fraction (LVEF). All LV volumes were indexed to body sur-
face area. The sphericity index (SI) was measured by div-
iding the length of the LV from the apex to the mitral
annulus by the width of the LV at the basal aspect of the
papillary muscles in the end-diastolic apical four-chamber
view. The wall motion score index (WMSI) was calculated
by dividing the sum of the scores by the number of seg-
ments per patient. The mitral valve regurgitant fraction
(MV RF) is the ratio of the mitral regurgitant volume di-
vided by the LV SV (where the mitral valve regurgitant
volume is the difference between the LV SV and the aortic
forward stroke volume). An absolute change in LVEF ≥5%
35 ± 6 months after revascularisation was considered to be
significant based on previously reported data about the ef-
fect of CABG on LV function [9], and taking into account
intra- and interobserver variability in LVEF measurements
by CMR [23,24]. When predicting significant LVEF im-
provement, a segment was considered viable if it either
had no LGE or had any LGE and produced CR during
LDD stimulation. The number of viable segments divided
by the total number of dysfunctional and revascularised
segments in a patient was expressed as a percentage that
was used to predict significant LVEF improvement. We
compared two groups: responders (i.e., patients with signifi-
cant LVEF improvement) and nonresponders (i.e., patients
without significant LVEF improvement (improvement of
LVEF < 5%)). The extent of LGE within each segment was
also measured by the two independent experienced investi-
gators on short-axis, contrast enhanced CMR images. Con-
trast enhanced pixels were defined as those with image
intensities > 2 SD above the mean image intensity in a re-
mote myocardial region in the same image. LGE was
assessed on a 5-grade scale [8] and analysed quantitatively
by dividing the hyperenhanced area, as measured by Argus
software-assisted tracings, by the total area in each segment
before being expressed as a percentage. Dysfunctional and
successfully revascularised segments without an increase in
the LGE area on the second and third CMR scans were
analysed. An improvement in wall motion at late follow-up
of at least 1 grade, with the exception of improvement from
grade 5 to grade 4 compared with baseline, was regarded asfunctional improvement or viability of the segment. The
LDD-CMR was regarded as indicative of viability or CR
when there was an improvement of 1 wall motion grade at
either the 5 or 10 μg/kg/min dose. Interobserver and
intraobserver agreement was assessed in 10 patients for the
transmural LGE grading, improvement in segmental and
global contractility and CR (Cohen’s κ, 0.82 – 0.88 interob-
server and 0.86 – 0.89 intraobserver). All reviewers of seg-
mental wall motion, CR, LGE and functional improvement
were blinded to each other and to the clinical data of the
patients. All discordant assessments were jointly reviewed.
Statistical analysis
All values are expressed as mean ± standard deviation
(SD). We used χ-squared tests to evaluate the trend in
likelihood of segmental improvement in the different
groups according to LGE, CR and baseline contractility.
We used the 0% LGE and mild hypokinesia groups as
references, so all other groups were related to those two.
The logistic regression equation was used to calculate
odds ratios, which expressed the likelihood of improve-
ment relative to the functional outcome of segments
without any LGE or CR or with mild hypokinesia.
In order to better evaluate the time course of segmental
functional improvement we reclassified segments accord-
ing to the time of improvement, dividing them into three
groups: 1) segments with early (at 6 ± 1 months) improve-
ment (this group incorporated segments with sustained
improvement during the entire study period as segments
with decreased segmental function at 35 ± 6 months),
2) segments with only late (at 35 ± 6 months) improve-
ment, 3) segments without improvement. This reclassi-
fication was needed in order not to miss segments with
early improvement despite a decrease in function at late
follow-up. The χ-squared tests with Bonferroni method
were used to evaluate the time course of segmental
functional improvement in relation to the extent of
myocardial scar and degree of contractile dysfunction
at baseline.
The different baseline and follow-up characteristics of
patients with and without significant improvement in
LVEF 6 ± 1 months and 35 ± 6 months after revascularisa-
tion were compared. The values from both patient groups
were expressed as mean ± SD. The effect of revascularisa-
tion was compared using a Wilcoxon signed-rank test.
The continuous variables that were not distributed nor-
mally were compared by using a nonparametric test. The
variables that differed significantly between groups were
included in a forward stepwise (Wald) logistic regression
analysis to determine the best independent predictor of
significant LVEF improvement. A receiver operating curve
(ROC) analysis was performed to validate the variables
with the best predictive ability. The predictor of global
functional recovery was treated as superior to the other
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nificantly greater.
To ensure the statistical power of the prediction of seg-
mental recovery, the required sample size of dysfunctional
and successfully revascularised segments was calculated.
For this purpose two logistic regression models were cre-
ated in which recovery of segmental function was consid-
ered as the dependent variable and the independent
variables were 50% threshold of either LGE (β0 = −0.754;
β1 = 4.229) or CR (β0 = 0.995; β1 = 3.582). We calculated
sample sizes for LGE and CR and considered the largest
calculated sample size (n = 276) that guaranteed accept-
able II type error in both models. All calculations were
performed using IBM SPSS statistics software (version 21)




At baseline, 714 segments (42 patients × 17 segments)
were available for analysis. Almost 45% of these seg-
ments (n = 319) were considered dysfunctional and were
successfully revascularised.
Functional improvement in segmental function
At the end of the study period, functional improvement
was observed in 209 (65.5%) segments, but the remaining
110 segments (34.5%) showed no signs of functional im-
provement (Figure 1). Compared with baseline, functional
improvement was seen in 90, 86, 76, 47, and 15% of seg-
ments with no, 1–25%, 26–50%, 51–75%, and 76–100%
LGE, respectively (Table 2). The likelihood of functional
improvement was inversely related to the LGE during the
entire follow-up: at the end of the study period, segmentsFigure 1 Flow chart of analysed segments according to the
presence of LGE, CR and late functional improvement at the
end of the study period.with 26–50%, 51–75%, and 76–100% LGE were 2.7
(1.3–5.8, p = 0.012), 9 (4.4–19.7, p < 0.0001), and 49
(18.1–130.5, p < 0.0001) times less likely to have func-
tional improvement than segments without any LGE.
The majority of the segments (157 of 185, 85%) with
CR at baseline had functional improvement at the end of
follow-up: segments with CR were 8.8 times (5.2 − 15.0,
p < 0.0001) more likely to have functional improvement
than segments without CR.
At the end of the study period, functional improve-
ment was documented in 78% of the segments with mild
hypokinesia, 54% in those with at least severe hypokine-
sia, and only 33% of those with akinesia or dyskinesia at
baseline. Functional improvement was inversely related
to baseline degree of segmental dysfunction during the
entire follow-up: at 35 ± 6 months, segments with akin-
esia or dyskinesia at baseline were 4 times (2.1–7.7,
p < 0.0001) less likely to have functional improvement
than segments with mild hypokinesia.
Additionally, we compared the predictive values of
CR, LGE50 (i.e. an LGE threshold value of 50%) and
LGE50 + CR for long-term functional recovery in the
same way as has previously been described in detail [12].
When the areas under the ROC curves are compared,
the combined viability prediction model (LGE50 + CR)
was significantly superior to CR alone in all the analysed
sets of segments (AUC 0.78/0.72, respectively, p = 0.028),
except the segments with an LGE from 26% to 75%
(p = 0.345) and an LGE from 1% to 75% (p = 0.301).
The combined viability prediction model (LGE50 + CR)
was statistically significantly superior to the LGE50 alone
in all the analysed sets of segments (p = 0.00001 in seg-
ments with any degree of LGE, p = 0.00007 in segments
with LGE from 26% to 75% and p = 0.00013 in segments
with LGE from 1% to 75%). The above-mentioned finding
is consistent with our previously published short-term re-
sults [12] and shows the superiority of LDD–CMR over
LGE–CMR in the prediction of short- and long-term seg-
mental recovery, especially in segments with an LGE from
1% to 75%. Relying on this finding we used both the CR
and the LGE for predicting whether a segment is viable or
not.
Time course of functional improvement
A total of 47 segments were dysfunctional at the end of
the study period. Twenty-two (47%) segments improved
at 6 ± 1 months but at the end of the study showed a de-
crease in segmental function, with six (27%) of these seg-
ments ending up at late follow-up with dysfunction of a
lesser degree than at baseline. None of the revascularised
normokinetic segments became dysfunctional at late
follow-up. The long-term follow-up revealed worsening
of segmental function in 5 (4%) initially normokinetic
and nonrevascularised segments.
Table 2 Functional improvement in segmental LV function at the end of the study period compared with baseline
(segmental functional improvement is expressed in absolute numbers of improved segments and a percentage of
baseline for every CMR scan according to LGE transmurality; n, number of dysfunctional segments at baseline)
CMR LGE
0% 1-25% 26-50% 51-75% 76-100%
Baseline n = 114 n = 7 n = 82 n = 68 n = 48
6 ± 1 months 93 (81.6%) 5 (71.4%) 58 (70.7%) 29 (42.7%) 8 (16.7%)
35 ± 6 months 9 (7.9%) 1 (14.3%) 4 (4.9%) 3 (4.4%) −1 (−2.1%)
Total 102 (89.5%) 6 (85.7%) 62 (75.6%) 32 (47.1%) 7 (14.6%)
Glaveckaite et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:83 Page 6 of 13
http://jcmr-online.com/content/16/1/83For the above-mentioned reason we reclassified the
segments according to the time of improvement, divid-
ing them into three groups: 1) segments with early (at
6 ± 1 months) improvement, 2) segments with only late
(at 35 ± 6 months) improvement, 3) segments without
improvement. According to this new classification, the
time course of functional improvement was consider-
ably protracted: the majority of the segments (193 of 319,
60.5%) improved in function early, while in a smaller
number of segments (32 of 319, 10%) functional improve-
ment was observed only at late follow-up (Figure 2). Al-
though functional improvement continued over the whole
study period in all LGE groups, the time course was
significantly more delayed in segments with LGE >75%
vs. ≤50% LGE at baseline (p = 0.005) (Figure 3A). The
majority (96 of 108, 89%) of the improvement in seg-
ments with 0–25% LGE was found at 6 ± 1 months, vs. only
43% (3 of 7) with improvement in segments with >75%
LGE. Conversely, more than one half (4 of 7, 57%) of the
total improvement in segments with >75% LGE occurredFigure 2 Likelihood of functional improvement after revascularisation
Early (at 6 ± 1 months; black bars) and late (at 35 ± 6 months; grey bars) funct
dysfunctional segments in each LGE category. All dysfunctional segments arebetween 6 ± 1 months and the final follow-up, vs. only a
small fraction (12 of 108, 11%) in segments with 0–25%
LGE (Figure 3A).
Although improvement continued over the whole
study period in all baseline contractility groups, the time
course was slightly more delayed in segments with akin-
esia and dyskinesia at baseline compared with hypokinesia
(p = 0.002) (Figure 3B). The majority (165 of 188, 88%) of
the improvement in segments with mild and severe hypo-
kinesia was found early, vs. only 12% (23 of 188) of
additional improvement at late follow-up. In contrast,
functional improvement in segments with baseline
akinesia or dyskinesia was less (12 of 24, 57%) in the
first 6 ± 1 months, but at the end of the study period
the relative improvement in those segments was greater
(9 of 21, 43%) compared with segments with less pro-
nounced dysfunction at baseline (Figure 3B).
The majority (156 of 185, 84%) of segments with CR
at baseline improved early, while in a small number of
segments (9 of 185, 5%) functional improvement wasin relation to the time course and segmental LGE at baseline.
ional improvement is expressed as a percentage of the total number of
included (n = 319).
Figure 3 (A) Time course of segmental functional improvement in relation to LGE at baseline, shown as the relative percentage of
improvement at 6 ± 1 months (black bars) and 35 ± 6 months (grey bars) follow-up. Only segments with functional improvement are
included (n = 209); *statistically significant differences between groups. (B) Time course of segmental functional improvement in relation to the
degree of contractile dysfunction at baseline, shown as the relative percentage of improvement at 6 ± 1 months (black bars) and 35 ± 6 months
(grey bars) follow-up. Data are shown for all segments with functional improvement at the end of the study period (first bar, n = 209) and separately
for segments with mild hypokinesia (second bar, n = 116), severe hypokinesia (third bar, n = 72) and for segments with akinesia and dyskinesia (fourth
bar, n = 21) before revascularisation. *Statistically significant differences between groups.
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the segments with early functional improvement, the
majority (156 of 193, 81%) had CR at baseline. In con-
trast, the majority of those segments (23 of 32, 72%)
with only late functional improvement had no CR at
baseline. Although improvement continued over the
whole study period in both groups (with and without
CR), the presence of CR was a predictor of earlier func-
tional improvement (p < 0.0001).Global left ventricular systolic function
Overall, the mean improvement in global LV function
35 ± 6 months after revascularisation was 13 ± 10%. Sig-
nificant LVEF improvement was observed in 32 (76%)patients (an example of a patient with significant im-
provement in LVEF (responder) is given in Figure 4).
Changes in LV function
At the end of the study period, significant differences
between the responder and nonresponder groups were
observed in LVEF (54 ± 11% vs. 35 ± 5%, respectively,
p < 0.001), EDV index (EDVI) (85 ± 24 ml/m2 vs. 124 ±
31 ml/m2, respectively, p = 0.001), ESV index (ESVI) (41 ±
18 ml/m2 vs. 82 ± 26 ml/m2, respectively, p < 0.001),
end-diastolic diameter index (EDDI) (2.6 ± 0.3 cm/m2
vs. 3 ± 0.4 cm/m2, respectively, p = 0.009), SI 0.55 ± 0.1
vs. 0.63 ± 0.1, respectively, p = 0.016), WMSI (1.4 ± 0.5
vs. 2.1 ± 0.3, respectively, p = 0.001) as well as a significant
difference in the number of segments with functional
Figure 4 Example of CMR viability and follow-up studies in a patient with significant improvement in LVEF (52 year old male without
previous MI, LVEF at baseline ~24%, and three vessel disease). There is severe hypokinesia in the anterior and inferior walls at baseline (first
column). Six months after revascularisation (complete revascularisation after CABG, 5 distal anastomoses) there is functional recovery in all segments of
the anterior and inferior walls (second column), with LVEF ~41%. Thirty-five months after revascularisation the contractile function of the anterior and
inferior walls is normal, with LVEF ~48%. There is no LGE in the above-mentioned segments (fourth column).
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nificant difference between responder and nonresponder
groups was also observed at late follow-up in the mean
New York Heart Association (NYHA) functional class
(1.3 ± 0.6 vs. 2.2 ± 0.8, respectively, p = 0.002).
Taking into account the changes in LV functional pa-
rameters within each group, significant improvements in
ESVI, SV, EF, MV RF and WMSI at late follow-up were
observed only in the responder group (Table 3). Changes
in ESVI, SV, EF and WMSI reached statistical signifi-
cance in the responder group relatively early (6 months
after revascularisation). Meanwhile, more time was
needed for a significant decrease in MV RF and add-
itional improvement in LVEF. Changes in SI, EDDI andTable 3 The dynamic changes in LV function 6 ± 1 and 35 ± 6
with and without significant improvement in LVEF
Responders Baseline 6 ± 1 months
LV EDVI (ml/m2) 84 ± 34 84 ± 23
LV ESVI (ml/m2) 55 ± 24 43 ± 19*
LV SV (ml) 67 ± 24 83 ± 20*
LVEF (%) 36 ± 8 51 ± 11*
MV RF (%) 22 ± 11 19 ± 12
WMSI 1.8 ± 0.4 1.4 ± 0.4*
Non-responders
LV EDVI (ml/m2) 116 ± 29 109 ± 24
LV ESVI (ml/m2) 77 ± 24 70 ± 19
LV SV (ml) 77 ± 22 77 ± 18
LVEF (%) 33 ± 6 36 ± 8*
MV RF (%) 21 ± 14 19 ± 7
WMSI 2.1 ± 0.4 1.9 ± 0.3*
*LV parameters that differed significantly between the baseline and 6 ± 1 month ev
and 35 ± 6 month evaluations; ***p values and mean differences ± standard deviatio
of the study period. Definitions of the terms and abbreviations are in the text.EDVI didn’t reach statistical significance in either group
(Table 3). Taking into account the long-term effect of
revascularisation on clinical symptoms in the responder
and nonresponder groups, changes in the angina pectoris
Canadian Cardiovascular Society (CCS) class (2.9 ± 0.5 to
0.4 ± 0.7, p < 0.0001 vs. 3.0 ± 0 to 1.1 ± 1.2, p = 0.01, re-
spectively) and heart failure NYHA functional class
(2.8 ± 0.6 to 1.3 ± 0.6, p < 0.0001 vs. 2.9 ± 0.3 to 2.2 ± 0.8,
p = 0.038, respectively) were significant.
Prediction of significant LVEF improvement
To assess the best CMR-based predictors of significant
LVEF improvement, we tested three parameters having
significant correlation with changes in LVEF at the endmonths after revascularisation within groups of patients
35 ± 6 months Mean diff. ± SD*** P value***
85 ± 24 1.6 ± 30 0.94
41 ± 18 14 ± 15 <0.001
92 ± 27 24 ± 24 <0.001
54 ± 11** 17 ± 8 <0.001
16 ± 10 5.0 ± 10 0.021
1.4 ± 0.5 0.4 ± 0.4 <0.001
124 ± 31 8.1 ± 28 0.445
82 ± 26 4.6 ± 21 0.575
84 ± 16 7 ± 19 0.359
35 ± 5 1.3 ± 3.8 0.113
21 ± 13 0.4 ± 18 0.859
2.1 ± 0.3 0.03 ± 0.3 0.779
aluations; **LV parameters that differed significantly between the 6 ± 1 month
n (SD) were calculated for LV parameters assessed at baseline and at the end
Figure 5 The areas under the ROC curves for cut-off values
of ≥50% (green line) and ≥55% (red line) of viable segments
for predicting significant improvement in global LV function
after revascularisation. Definitions of the terms are in the text.
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lute number of viable segments in a patient (r = 0.40,
p = 0.008), the percentage of viable segments from all
dysfunctional and revascularised segments in a patient
(r = 0.56, p < 0.0001) and the number of viable + normal
segments in a patient (r = 0.50, p = 0.001). Forward step-
wise (Wald) logistic regression analysis was performed to
determine the best independent predictor of significant
LVEF improvement. This analysis revealed that the per-
centage of viable segments from all dysfunctional and
revascularised segments in a patient was a significant pre-
dictor of LVEF improvement ≥5% after revascularisation
(p = 0.009). Meanwhile, the absolute number of viable seg-
ments in a patient (p = 0.14) and the number of viable +
normal segments in a patient (p = 0.37) were not good
predictors of significant LVEF improvement. The other LV
parameters put into the forward stepwise (Wald) logistic
regression analysis, EDVI, ESVI, and WMSI (that differed
between the responder and nonresponder groups at base-
line) were not good predictors of significant LVEF im-
provement after revascularisation.
Additionally, using ROC analysis, the AUC for the per-
centage of viable segments was 0.78 (p = 0.008) com-
pared to AUC 0.63 for the number of viable segments
(p = 0.22). An additional ROC analysis was used to de-
fine a threshold for the percentage of viable segments in
a patient that possessed the optimal sensitivity and spe-
cificity for predicting global functional LV recovery. Ap-
plying a cut-off of ≥50% viable segments yielded 72%
sensitivity and 60% specificity (AUC 0.66, p = 0.132),
while a cut-off of ≥55% viable segments yielded 72% sen-
sitivity and 80% specificity (AUC 0.76, p = 0.014)
(Figure 5).
Discussion
This is the first prospective study that used CR and
LGE, both assessed by CMR, to predict segmental and
global LV functional improvement 35 ± 6 months after
revascularisation in patients with chronic ischemic LVD.
Prediction of segmental functional improvement
The fundamental study by Kim et al. [8] was the first to
demonstrate a progressive loss of functional recovery
with increasing transmural extent of LGE. Furthermore,
they demonstrated that although 78% of segments with-
out evidence of scar had improved contractility at
3 months, a significant proportion still did not. Another
study by Bondarenko et al. [10] found a relatively low
improvement rate at 3 months (56% of segments without
LGE); however, almost all segments without LGE (93%)
showed functional improvement after 24 ± 12 months of
follow-up. A study done by Selvanayagam et al. [9] re-
ported a high percentage of improved segments (82%)
6 months after surgical revascularisation. Our studyshowed comparable high percentages of improved seg-
ments – 82% of segments without LGE at 6 ± 1 months
and 90% of segments without LGE 35 ± 6 months after
revascularisation. Performing CMR scans later and ex-
cluding patients with procedure-related injury or injury at
late follow-up, as we expected, resulted in a high propor-
tion of segments with functional improvement after revas-
cularisation, particularly at the end of the study period.
The significant inverse relationship between the likelihood
of segmental functional recovery and the LGE or the
degree of contractile dysfunction at baseline reported in
our study does not contradict the findings of other
studies [8-10,13].
We ascertained the predictive accuracy of preproce-
dural LGE and CR for the recovery of segmental func-
tion in a cohort (mean age 65 years with LVEF about
36%, most of the patients with 3 vessel disease and in
the NYHA III functional class) typically considered for
viability assessment before revascularisation. The defin-
ition of a viable segment is based on previous works
[11-13] showing that in patients with <75% LGE, the
additional assessment of CR by LDD-CMR improves
predictive accuracy over LGE imaging alone. For prac-
tical purposes we did not complicated this definition by
including cut-off values of LGE into the definition of vi-
able segment because, according to our present research,
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CR during LDD-CMR and improved in segmental func-
tion at late follow-up. Predicting segmental functional
improvement 6 ± 1 months after revascularisation in our
cohort and using the above-mentioned definition of vi-
able segment, we obtained sensitivity, specificity, PPV
and NPV of 86%, 71%, 82% and 76%, respectively. Predict-
ing segmental functional improvement 35 ± 6 months
after revascularisation, we obtained sensitivity, specificity,
PPV and NPV of 80%, 70%, 83% and 65%, respectively.
Other studies with longer than a 6 month follow-up done
by Bondarenko at al. [10] (viability criteria was LGE <50%,
follow-up 24 ± 12 months) and Knuesel et al. [19] (viability
criteria was viable rim > 4.5 mm, follow-up 11 ± 2 months)
showed slightly lower PPV of 77% and 78% and slightly
higher NPV of 73% and 78%, respectively, than our study.
Differences in sensitivity, specificity, PPV and NPV ob-
tained using the same viability definition but different
follow-up periods in our study is influenced by the pro-
longed time course of improvement and the 16 segments
(5% of all dysfunctional and revascularised segments) that
ended up with dysfunction at late follow-up despite im-
provement 6 months after revascularisation. The addition
of LDD-CMR to the LGE-CMR protocol didn’t meaning-
fully increase the diagnostic accuracy of viability detection
compared with other studies that used only LGE-CMR
based viability markers [8-11,15,26,27]. The reason for this
with other studies with comparable diagnostic accuracy a
despite more sophisticated viability assessment protocol
and the much longer follow-up time in our study might
be the complexity of recovering hibernating myocardium.
As we know, the recovery of viable myocardium in the
setting of chronic LVD is influenced by a number of add-
itional factors (long-term graft failure or restenosis, dur-
ation of hibernation, ongoing LV remodelling, timing of
repeated assessment, etc.) and none of the available im-
aging modalities boast optimal accuracy for predicting re-
gional or global functional improvement [2].
Time course of functional improvement
The time course of segmental functional improvement
in our study was protracted. A comparable percentage of
segments continued to show improvement throughout
the study period in all LGE groups (Figure 2). However,
their relative time courses differed considerably: the time
course was significantly more delayed in segments with
more extensive LGE (p = 0.005), more severe contractile
dysfunction at baseline (p = 0.002) (Figure 3) and the ab-
sence of CR at baseline (p < 0.0001). Thus, the presence
of CR is a predictor of early functional improvement.
The inverse relationship between segmental functional
improvement and both baseline LGE and contractile
dysfunction could be explained by the fact that more ex-
tensive LGE correlates with more severe contractiledysfunction (r = 0.52, p < 0.0001). We found 52% (25 of 48)
akinetic or dyskinetic segments in the group with LGE
more than 75%; however, only 7% of segments were akin-
etic or dyskinetic in the group with LGE ≤50%. Similarly, a
previous long-term follow-up study done Bondarenko at al.
[10] suggested that segments with a higher baseline amount
of scarring require a longer time to recover. The rationale
for this observation is that the degree of degenerative
change at the cellular and subcellular levels (e.g., increased
extracellular matrix, with replacement of cardiomyocytes
by fibrosis) in hibernating myocardium influences the time
course of functional improvement [19]. In order for func-
tional improvement to occur it is not the scar per se but the
unenhanced viable rim that is important – both the thick-
ness and degree of degenerative changes in the viable rim
directly influence whether the segment will recover after
revascularisation [19,27]. We observed a weak and nonsig-
nificant correlation (r = 0.22, p = 0.128) between the
thickness of the unenhanced viable rim and functional
improvement in segments with LGE >75%, confirming
that not only the thickness but also the degenerative
changes in the viable rim are important for functional
improvement. As overall improvement in segments with
(almost) transmural LGE is low (Figure 3), research study-
ing the subtle morphological changes in the unenhanced vi-
able rim in this LGE group carries more academic than
practical value.
Prediction of global functional improvement
We found significant changes in the mean LVEF after
revascularisation, even at late follow-up (13 ± 10%), which
suggests that the late improvement in segmental function
was sufficient for additional global improvement at the
end of the study period despite the 47 segments that
ended up with a larger degree of contractile dysfunction
compared with baseline. As has been published previously
[12], at baseline patients in the nonresponder group
(n = 10) had more remodelled left ventricles, lower
LVEF, higher LV volume indexes and higher WMSI
compared with the responder group (n = 32). At the
end of the study period significant difference between
the responder and nonresponder groups were observed in
LVEF, LV volumes and diameter indexes, SI, WMSI and
the number of segments with functional recovery. Thus,
patients in the nonresponder group had severely remod-
elled left ventricles at baseline (ESV 153 ± 46 ml, ESVI
77 ± 24 ml/m2) and didn’t show any reverse remodel-
ling at late follow-up (Table 3). Similarly, Bax at al. [28]
suggested that in patients with substantial viability
(≥25% LV), sub-groups with extensive pre-operative re-
modelling (ESV >140 ml) do not show substantial im-
provement in LVEF following CABG. Severely dilated
LV often do not improve their function after revascular-
isation, irrespective of the quantity of hibernating
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revascularisation is associated with improved prognosis
[28-30]. Additionally, subendocardial scarring can pre-
vent systolic thickening at rest, but revascularisation of
the mid-myocardial and epicardial layers – which main-
tains their viability – helps prevent scar expansion [31]
and, consequently, even though segmental contractile
recovery may not occur, the absence of further cavity
dilatation is in fact a benefit of revascularisation [30].
In our study we didn’t find ongoing remodelling in the
nonresponder group because changes in LV volumes
were insignificant during the entire follow-up. The ab-
sence of further LV cavity dilatation together with sig-
nificant decreases in angina pectoris CCS class and
heart failure NYHA functional class may show a benefit
of revascularisation in this group. The value of using
cut-off values for LV volumes alongside the degree of
viability in more remodelled ventricles in order to decide
regarding revascularisation should be tested in future
studies.
In contrast, patients in the responder group had sig-
nificant trends of improvement in ESVI, SV, LVEF, and
WMSI at the 6 ± 1 month and 35 ± 6 month follow-up.
The trend towards a decrease in MV RF was only ob-
served at the end of the study period (p = 0.021). If we
define reverse remodelling as ≥15% reduction in the LV
end-systolic volume, patients in the responder group ex-
perienced reverse remodelling (mean ESV at baseline
112 ± 51 ml vs. 87 ± 40 ml at 6 ± 1 months vs. 83 ± 37 ml
at 35 ± 6 months; reduction in mean ESV by ~22% be-
tween baseline and 6 ± 1 month follow-up and by ~26%
between baseline and 35 ± 6 month follow-up).
Significant improvement in global LV function after
revascularisation requires a substantial amount of viable
myocardium. Long-term data are scarce, since most
CMR-based viability studies have focused on short-term
(≤6 months after revascularisation) changes in regional
and global function [8,26] or found only small changes
in mean global LV function at late follow-up [10]. In our
study group, there was a significant positive relation
(r = 0.56, p < 0.0001) between the amount of dysfunc-
tional but viable myocardium at baseline, expressed as
the percentage of viable segments from all dysfunc-
tional and revascularised segments in a patient, and
improvement in the LVEF at late follow-up. As we
were basing our experiments on a different study de-
sign and relying on our segmental functional recovery
prediction results published previously [12], we incor-
porated LGE-CMR and LDD-CMR data. We analysed
different predictors of LVEF improvement ≥5% after
revascularisation including the percentage of viable
segments [12], the absolute number of viable segments
and the number of viable + normal segments in a patient
[26]. According to our analysis, the significant independentpredictor of LVEF improvement ≥5% after revascularisation
at the end of the study was the percentage of viable
segments with a cut-off value of ≥55% viable segments,
yielding 72% sensitivity and 80% specificity (AUC 0.76,
p = 0.014, Figure 5). The predictor of global functional
recovery in our study had a lower predictive value than
the predictor used in a study conducted by Pegg et al.
[26]; this could be explained by a difference in the studies’
definitions of significant LVEF improvement (i.e., ≥ 3%
change in LVEF [26] versus ≥ 5% change in our cohort)
and different follow-up times (i.e., 6 months [26] versus
35 ± 6 months in our study). Interestingly, the percentage
of viable segments as a predictor of significant improve-
ment in LVEF reached statistical significance only at the
end of the study period, compared with the interim data
at 6 months (p = 0.054) [12]. Thus, we think that a cut-off
of ≥55% viable segments is a good predictor of global
functional improvement, and could be relevant for clini-
cians making decisions regarding revascularisation in pa-
tients with impaired LV function in everyday practice.
Limitations
The major limitation of the present study is the small
sample size. However, this sample size is comparable to
previously published studies that used LGE-CMR and
LDD-CMR in patients with chronic ischemic LVD
undergoing revascularisation [11,13,27]. Additionally,
319 at baseline dysfunctional and successfully revascu-
larised segments were available for statistical analysis,
which is more than the required sample size (n = 276) to
ensure statistically meaningful predictions of segmental
recovery.
In our study, the verification of functional recovery
was performed at 6 ± 1 and 35 ± 6 months after revascu-
larisation. The use of two follow-up evaluations for ven-
tricular function with a relatively long period between
them may lead to an underestimation of the true rate of
functional recovery. The time course of full recovery
may be up to 24 ± 12 months [10], and with a longer
follow-up period (i.e. 35 months instead of 24 months)
some amount of possible recovery could be missed be-
cause late graft failure or stent restenosis can negatively
affect LV function. Although restenosis/graft occlusion
was excluded through invasive procedures at late follow-
up in five patients (12%), their non-invasive follow-up
revealed that they were free of symptoms or signs indi-
cating recurrent ischemia or major adverse cardiac
events. Not one patient from our study group mani-
fested any new LGE zones at late follow-up. The longer
follow-up period compared with previous studies repre-
sents real clinical practice and gives insights not only
into the time course of segmental and global LV func-
tional recovery but also into the long-term sustainability
of recovery after revascularisation.
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sation does not necessarily result in establishing circula-
tion to all segments, especially when a significantly
reduced flow or reduced flow reserve is present in small
arterial branches. This is a limitation of our and most
other viability studies. By performing myocardial stress
perfusion at follow-up is it possible to solve this problem.
But then it will be extremely difficult to collect a sufficient
sample size and this thoroughly selected cohort won’t rep-
resent real clinical practise.
The visual assessment of wall motion is also a limita-
tion of the present study. A quantitative assessment of
segmental LV function may be more reliable for asses-
sing subtle changes in contractility, but this approach is
rarely used in clinical practice and may not represent
the standard viability assessment before revascularisation
performed on a daily basis.
Conclusions
In patients with chronic ischaemic LVD, improvement of
dysfunctional but viable myocardium can be consider-
ably delayed. Both the likelihood and the time course of
functional improvement are related to the baseline
amount of scarring, presence of CR and degree of con-
tractile dysfunction, as visualized by CMR. A cut-off
value of ≥55% viable segments from all dysfunctional
and revascularised segments in a patient predicts both
the long-term significant improvement in LVEF and the
reverse LV remodelling. Follow-up CMR scan scheduled
6 months after revascularisation is not long enough to
assess the full potential of segmental and global func-
tional recovery. Combination of LDD-CMR and LGE-
CMR is a simple and powerful tool for identifying which
patients with impaired LV function will benefit from
revascularisation.
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